You have 9 free searches left this month | for more free features.

Myeloid malignancies

Showing 1 - 25 of 4,524

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (Cyclophosphamide, Mesna, Filgrastim)

Not yet recruiting
  • Myeloid Malignancies
  • +3 more
  • Houston, Texas
    M D Anderson Caner Center
Feb 8, 2022

Myeloid Leukemia, Acute, Chronic Myeloid Leukemia, MDS Trial in Saint Petersburg (Bendamustine Hydrochloride, Cyclophosphamid)

Recruiting
  • Myeloid Leukemia, Acute
  • +3 more
  • Saint Petersburg, Russian Federation
    RM Gorbacheva Research Institute
Apr 4, 2022

Disease-free Survival Trial in Shanghai (MBF-RIC)

Recruiting
  • Disease-free Survival
  • Shanghai, Shanghai, China
  • +1 more
Jun 28, 2022

Leukemia Trial (Donor Enriched Activated Natural Killer Cell Infusion)

Not yet recruiting
  • Leukemia
  • Donor Enriched Activated Natural Killer Cell Infusion
  • (no location specified)
May 10, 2022

MDS, MDS/MPN Crossover Syndromes Trial in Cleveland (5-azacytidine, Decitabine)

Recruiting
  • Myelodysplastic Syndromes
  • MDS/MPN Crossover Syndromes
  • Cleveland, Ohio
    Cleveland Medical Center, University Hospitals Seidman Cancer Ce
Aug 10, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Adelaide (IMG-7289, All-trans retinoic acid)

Completed
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Adelaide, South Australia, Australia
    Royal Adelaide Hospital
Jan 24, 2022

Primary Myelofibrosis, Secondary Myelofibrosis, Myeloid Malignancies Trial in Rochester (Imetelstat)

Completed
  • Primary Myelofibrosis
  • +2 more
  • Rochester, Minnesota
    (unnamed)
Aug 24, 2021

Leukemia, Myeloid, Acute Trial (GSK3745417)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • (no location specified)
Jun 15, 2022

Intravenous Busulfan And Fludarabine Myeloablative Conditioning

Completed
  • Acute Myeloid Leukemia
  • +3 more
    • (no location specified)
    Mar 16, 2022

    Leukemia, Erythroblastic, Acute, MDS Trial in New York (5-Azacytidine, Fludarabine, Melphalan)

    Completed
    • Leukemia, Erythroblastic, Acute
    • Myelodysplastic Syndromes
    • New York, New York
      Weill Cornell Medical College
    Aug 25, 2021

    Myeloid Malignancy Trial in United States (APR-246, Venetoclax, Azacitidine)

    Completed
    • Myeloid Malignancy
    • New Haven, Connecticut
    • +7 more
    Jan 18, 2022

    Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease, Mast Cell Leukemia Trial

    Active, not recruiting
    • Aggressive Systemic Mastocytosis
    • +3 more
    • Stanford, California
    • +10 more
    Mar 25, 2022

    Myeloid Malignancy, MDS, Myelofibrosis Trial in Boston (Navitoclax, Venetoclax, Decitabine)

    Recruiting
    • Myeloid Malignancy
    • +4 more
    • Boston, Massachusetts
    • +2 more
    Jul 21, 2022

    Leukemia Trial in France, United States (BAY2402234)

    Terminated
    • Leukemia
    • Bronx, New York
    • +4 more
    Dec 20, 2021

    High Risk Myeloid Malignancies, Cord Blood Transplant Trial in New York (ECT-001-CB (UM171-Expanded Cord Blood Transplant))

    Recruiting
    • High Risk Myeloid Malignancies
    • Cord Blood Transplant
    • ECT-001-CB (UM171-Expanded Cord Blood Transplant)
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Jan 12, 2022

    Myeloid Malignancies Trial in Australia, United Kingdom, United States (Magrolimab, Azacitidine, Venetoclax)

    Recruiting
    • Myeloid Malignancies
    • Magrolimab
    • +6 more
    • Birmingham, Alabama
    • +12 more
    Apr 6, 2022

    Acute Myeloid Leukemia Trial in Boston (Regorafenib)

    Active, not recruiting
    • Acute Myeloid Leukemia
    • Boston, Massachusetts
      Massachusetts general Hospital
    Sep 4, 2020

    Myelodysplastic Syndrome RAEB-I or RAEB-II, Refractory Acute Myeloid Leukemia, Refractory CML Myeloid Blast Crisis Trial in

    Completed
    • Myelodysplastic Syndrome RAEB-I or RAEB-II
    • +2 more
    • GM-CSF secreting leukemia vaccine
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Jan 28, 2022

    Relapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic Syndrome Trial in Worldwide (AMG 330)

    Recruiting
    • Relapsed/Refractory AML
    • +2 more
    • AMG 330
    • Birmingham, Alabama
    • +10 more
    Mar 3, 2022

    Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)

    Recruiting
    • Acute Myeloid Leukemia
    • +3 more
    • Edmonton, Alberta, Canada
    • +1 more
    Nov 29, 2021

    Myeloid Malignancies, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia Trial in Hackensack (Fludarabine and Busulfan

    Active, not recruiting
    • Myeloid Malignancies
    • +4 more
    • Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)
    • Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
    • Hackensack, New Jersey
      John Theurer Cancer Center at Hackensack University Medical Cent
    Feb 25, 2022

    Myeloid Malignancies Trial in Italy (GvHD prophylaxis)

    Recruiting
    • Myeloid Malignancies
    • GvHD prophylaxis
    • Alessandria, Italy
    • +32 more
    Aug 19, 2021

    Myeloid Malignancies, Lymphoid Malignancies Trial in Durham (NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001)

    Recruiting
    • Myeloid Malignancies
    • Lymphoid Malignancies
    • NK Cell enriched-DLI only
    • NK-DLI + DUK-CPG-001
    • Durham, North Carolina
      Duke University Health System
    Mar 8, 2022

    Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in United States (E7820)

    Recruiting
    • Acute Myeloid Leukemia
    • +2 more
    • Miami, Florida
    • +6 more
    Apr 25, 2022